Inventor
BERLIN MICHAEL
US28 patents
⚠️ This page may combine multiple inventors who share the name “BERLIN MICHAEL”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ARVINAS OPERATIONS INC
19 patentsUS11981683B2May 14, 2024
Indazole based compounds and associated methods of use
ARVINAS OPERATIONS INC5 citations83
US11191741B2Dec 7, 2021
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
ARVINAS OPERATIONS INC3 citations73
US11707452B2Jul 25, 2023
Modulators of alpha-synuclein proteolysis and associated methods of use
ARVINAS OPERATIONS INC2 citations72
US11427548B2Aug 30, 2022
Compounds and methods for the targeted degradation of androgen receptor
ARVINAS OPERATIONS INC2 citations72
US11858940B2Jan 2, 2024
Selective modulators of mutant LRRK2 proteolysis and associated methods of use
ARVINAS OPERATIONS INC2 citations71
US11912699B2Feb 27, 2024
Tau-protein targeting compounds and associated
ARVINAS OPERATIONS INC2 citations69
US12171831B2Dec 24, 2024
Compounds and methods for the targeted degradation of bromodomain- containing proteins
ARVINAS OPERATIONS INC0 citations62
US11857519B2Jan 2, 2024
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
ARVINAS OPERATIONS INC0 citations62
US11554171B2Jan 17, 2023
Compounds and methods for the targeted degradation of bromodomain-containing proteins
ARVINAS OPERATIONS INC0 citations62
US12594264B2Apr 7, 2026
Modulators of alpha-synuclein proteolysis and associated methods of use
ARVINAS OPERATIONS INC0 citations61
US12264157B2Apr 1, 2025
Compounds and methods for the enhanced degradation of targeted proteins
ARVINAS OPERATIONS INC0 citations61
US11512083B2Nov 29, 2022
Compounds and methods for the enhanced degradation of targeted proteins
ARVINAS OPERATIONS INC1 citations61
US12589156B2Mar 31, 2026
Benzimidazole and benzimidazolone based protac compounds for the targeted degradation of leucine rich repeat kinase 2 (LRRK2)
ARVINAS OPERATIONS INC0 citations60
US12559506B2Feb 24, 2026
Indazole based compounds and associated methods of use
ARVINAS OPERATIONS INC0 citations60
US12473294B2Nov 18, 2025
Selective modulators of mutant LRRK2 proteolysis and associated methods of use
ARVINAS OPERATIONS INC0 citations60
US12559486B2Feb 24, 2026
Tau-protein targeting compounds and associated methods of use
ARVINAS OPERATIONS INC0 citations58
US12441708B2Oct 14, 2025
Cereblon ligands and bifunctional compounds comprising the same
ARVINAS OPERATIONS INC0 citations52
US12539292B2Feb 3, 2026
BRM targeting compounds and associated methods of use
ARVINAS OPERATIONS INC0 citations51
US12310975B2May 27, 2025
Modulators of BCL6 proteolysis and associated methods of use
ARVINAS OPERATIONS INC0 citations51
MERCK SHARP & DOHME
5 patentsUS10472347B2Nov 12, 2019
Aminopyrazine compounds with A2A antagonist properties
MERCK SHARP & DOHME5 citations72
US10138212B2Nov 27, 2018
Aminoquinazoline compounds as A2A antagonist
MERCK SHARP & DOHME2 citations70
US9676780B2Jun 13, 2017
Piperazine-substituted [1,2,4]triazolo[1,5-C]quinazolin-5-amine compounds with A2A antagonist properties
MERCK SHARP & DOHME2 citations61
US11498923B2Nov 15, 2022
Substituted imidazo[1,2-c]quinazolines as A2A antagonists
MERCK SHARP & DOHME0 citations47
US10688082B2Jun 23, 2020
Aminopyrazine compounds with A2A antagonist properties
MERCK SHARP & DOHME0 citations39
ARVINAS INC
3 patentsUS10772962B2Sep 15, 2020
Compounds and methods for the targeted degradation of bromodomain-containing proteins
ARVINAS INC15 citations94
US10730870B2Aug 4, 2020
Compounds and methods for the enhanced degradation of targeted proteins
ARVINAS INC25 citations93
US11458123B2Oct 4, 2022
Tau-protein targeting PROTACs and associated methods of use
ARVINAS INC2 citations71